Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$1.45 +3.6%	$1.32	$1.05 ▼ $8.79	$97.99M	-0.11	204,297 shs	145,674 shs
IPA ImmunoPrecise Antibodies	$1.64 -1.2%	$1.22	$0.27 ▼ $2.41	$75.69M	0.49	2.14 million shs	1.01 million shs
LGVN Longeveron	$1.64 +0.9%	$1.39	$1.14 ▼ $3.04	$24.41M	0.23	831,428 shs	119,480 shs
ONCY Oncolytics Biotech	$0.99 -2.9%	$0.80	$0.33 ▼ $1.53	$96.43M	1.09	1.31 million shs	537,614 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	0.00%	0.00%	+13.28%	+14.17%	+144,999,900.00%
IPA ImmunoPrecise Antibodies	0.00%	-24.07%	+22.85%	+257.22%	+107.86%
LGVN Longeveron	0.00%	-2.10%	+24.33%	+4.81%	-47.76%
ONCY Oncolytics Biotech	0.00%	-5.71%	+9.88%	+80.00%	-4.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLYM Climb Bio	2.3381 of 5 stars	3.6	0.0	0.0	2.5	1.3
IPA ImmunoPrecise Antibodies	2.0204 of 5 stars	3.5	3.0	1.8	0.0	0.6
LGVN Longeveron	2.2837 of 5 stars	3.6	2.0	1.7	1.7	0.6
ONCY Oncolytics Biotech	2.4429 of 5 stars	3.4	5.0	2.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.25	Buy	$9.00	520.69% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	143.90% Upside
LGVN Longeveron	3.25	Buy	$8.67	430.07% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	337.71% Upside

Current Analyst Ratings Breakdown

Latest LGVN, ONCY, IPA, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$7.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
IPA ImmunoPrecise Antibodies	$17.59M	4.30	N/A	N/A	$0.93 per share	1.76
LGVN Longeveron	$2.39M	10.21	N/A	N/A	$1.47 per share	1.11
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$73.90M	-$2.38	N/A	N/A	N/A	N/A	-43.95%	-42.94%	8/13/2025 (Estimated)
IPA ImmunoPrecise Antibodies	-$20.13M	-$0.68	N/A	N/A	N/A	-122.10%	-40.62%	-22.19%	9/15/2025 (Estimated)
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-760.72%	-85.07%	-70.74%	8/13/2025 (Estimated)
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	8/7/2025 (Estimated)

Latest LGVN, ONCY, IPA, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	CLYM Climb Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	LGVN Longeveron	-$0.35	N/A	N/A	N/A	$0.41 million	N/A
8/7/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.10	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q4 2025	IPA ImmunoPrecise Antibodies	-$0.02	-$0.04	-$0.02	-$0.04	$7.89 million	$5.06 million
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	14.25	14.25
IPA ImmunoPrecise Antibodies	0.49	2.08	2.11
LGVN Longeveron	N/A	5.61	5.61
ONCY Oncolytics Biotech	N/A	3.20	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
IPA ImmunoPrecise Antibodies	6.70%
LGVN Longeveron	10.01%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	0.80%
IPA ImmunoPrecise Antibodies	6.83%
LGVN Longeveron	11.20%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	67.58 million	67.04 million	N/A
IPA ImmunoPrecise Antibodies	80	46.15 million	43.00 million	Not Optionable
LGVN Longeveron	20	14.93 million	13.26 million	Not Optionable
ONCY Oncolytics Biotech	30	97.41 million	97.31 million	Not Optionable

LGVN, ONCY, IPA, and CLYM Headlines

Recent News About These Companies

Analysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Target Price at $4.33

August 2 at 2:06 AM | americanbankingnews.com

Oncolytics Biotech (ONCY) Projected to Post Earnings on Thursday

July 31 at 3:38 AM | marketbeat.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Brokerages

July 30, 2025 | marketbeat.com

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

July 29, 2025 | prnewswire.com

Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.8% - Time to Buy?

July 29, 2025 | marketbeat.com

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential

July 25, 2025 | cantechletter.comC

Cancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025

July 24, 2025 | baystreet.ca

Oncolytics Biotech Inc.: Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules

July 24, 2025 | finanznachrichten.de

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

July 24, 2025 | newswire.ca

Oncolytics Biotech Highlights Pelareorep’s Potential in Pancreatic Cancer at KOL Event

July 23, 2025 | tipranks.com

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

July 23, 2025 | prnewswire.com

Oncolytics Biotech Regains Nasdaq Compliance as of July 22, 2025

July 22, 2025 | tipranks.com

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

July 22, 2025 | prnewswire.com

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

July 16, 2025 | prnewswire.com

Oncolytics Biotech Inc. (ONCY) - Yahoo Finance Canada

July 11, 2025 | ca.finance.yahoo.com

USA News Group: Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

July 10, 2025 | finanznachrichten.de

Oncolytics Biotech to Host Webinar on Pelareorep’s Potential in Cancer Treatment

July 10, 2025 | tipranks.com

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

July 10, 2025 | prnewswire.com

Oncolytics Biotech Highlights Promising Pelareorep Data in Cancer Treatment

July 10, 2025 | theglobeandmail.com

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - The Globe and Mail

July 9, 2025 | theglobeandmail.com

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

July 8, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal
By Gabriel Osorio-Mazilli | July 8, 2025
View Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
By Brian O'Connell | July 16, 2025
View 3 Fast Food Stocks That Won’t Give You Indigestion Right Now

LGVN, ONCY, IPA, and CLYM Company Descriptions

Climb Bio NASDAQ:CLYM

$1.45 +0.05 (+3.57%)

As of 08/1/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

ImmunoPrecise Antibodies NASDAQ:IPA

$1.64 -0.02 (-1.20%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.58 -0.05 (-3.35%)

As of 08/1/2025 07:58 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Longeveron NASDAQ:LGVN

$1.64 +0.02 (+0.93%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.63 -0.01 (-0.31%)

As of 08/1/2025 07:39 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Oncolytics Biotech NASDAQ:ONCY

$0.99 -0.03 (-2.94%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+1.52%)

As of 08/1/2025 07:56 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time